• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » UPDATE: FDA panel green-lights BSX on expanded CRT-D indication

UPDATE: FDA panel green-lights BSX on expanded CRT-D indication

March 19, 2010 By MassDevice staff

A Food & Drug Administration panel approved a Boston Scientific Corp. (NYSE:BSX) bid to expand the indication of its cardiac resynchronization therapy defibrillators to cover patients suffering from milder forms of heart failure.

The decision from the FDA’s circulatory systems devices panel came late Thursday afternoon. The company’s current indication is for patients diagnosed with New York Heart Assn. Class III or Class IV heart failure, classified as the most severe cases. An expanded indication opens up a significant new market opportunity for BSX, according to company officials.

It’s a much-needed boost for for Boston Scientific’s cardiac rhythm management business as it struggles through a rough week. The company voluntarily stopped all shipments of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators and pulled its inventory from the field after discovering that it missed a pair of filings with the FDA.

News reports estimate that the hold could last as long as a month as BSX files for a 30-day supplement to its pre-market approval from regulators to clear up the paperwork issue. Agency officials have said they are not aware of any safety concerns regarding the devices.

The approved expansion of the CRT-D indication seemed likely March 16, when an FDA panel released a report generally supportive of the Natick, Mass.-based medical device giant’s Madit-CRT study last fall, writing that it provided sound evidence of the devices’ effectiveness in reducing heart failure events during a clinical trial that involved more than 1,800 patients.

The panel was less certain about the overall benefits to a wider patient population suffering from milder forms of heart failure. But it was evidently satisfied with the answers given by the company today and chose to rule in its favor.

Boston Scientific spokesman Dave Knutson told MassDevice that the panel’s recommendation still needs to be approved by the FDA before the company can begin actively marketing the device to new patient populations, something he expected to happen by the middle of 2010.

“If it gets approved, then it’ll be a great day for patients, because physicians will have the ability to implant in Phase I and II patients,” Knutson told us. “Hopefully this will keep them healthier longer.”

If the FDA goes along, Knutson said the company will ramp up its sales efforts to take advantage of the expanded indication.

He called it a significant achievement for the company.

“Any time you complete a big clinical trial like this and an FDA panel agrees that you had a robust study and unanimously votes to approve it, it’s a big win,” Knutson said. “These massive studies don’t come along every day.”

Filed Under: Business/Financial News, News Well Tagged With: Boston Scientific, Cardiac Rhythm Management

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy